Allen Capital Group LLC Makes New Investment in Organon & Co. (NYSE:OGN)

Allen Capital Group LLC purchased a new position in shares of Organon & Co. (NYSE:OGN) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,057 shares of the company’s stock, valued at approximately $150,000.

A number of other large investors also recently modified their holdings of OGN. Robeco Institutional Asset Management B.V. acquired a new position in Organon & Co. in the 4th quarter worth about $2,263,000. Wealth Effects LLC increased its stake in shares of Organon & Co. by 13.9% in the fourth quarter. Wealth Effects LLC now owns 58,578 shares of the company’s stock valued at $874,000 after buying an additional 7,160 shares during the period. Pacer Advisors Inc. raised its holdings in Organon & Co. by 94,482.1% in the 4th quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock valued at $166,391,000 after buying an additional 11,140,388 shares during the last quarter. KBC Group NV boosted its position in Organon & Co. by 66.6% during the 4th quarter. KBC Group NV now owns 12,899 shares of the company’s stock worth $192,000 after buying an additional 5,155 shares during the period. Finally, Blue Trust Inc. grew its holdings in Organon & Co. by 107.6% during the 4th quarter. Blue Trust Inc. now owns 7,599 shares of the company’s stock worth $113,000 after acquiring an additional 3,938 shares during the last quarter. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Stock Performance

NYSE:OGN opened at $15.85 on Thursday. The company has a market capitalization of $4.08 billion, a PE ratio of 3.14, a P/E/G ratio of 0.87 and a beta of 0.76. Organon & Co. has a fifty-two week low of $13.87 and a fifty-two week high of $23.10. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. The company has a 50 day simple moving average of $15.44 and a two-hundred day simple moving average of $17.98.

Organon & Co. (NYSE:OGN) last announced its earnings results on Thursday, October 31st. The company reported $0.87 earnings per share for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). The firm had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.56 billion. Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. Organon & Co.’s quarterly revenue was up 4.1% on a year-over-year basis. During the same period in the prior year, the business earned $0.78 EPS. Research analysts anticipate that Organon & Co. will post 3.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Organon & Co. currently has a consensus rating of “Hold” and a consensus price target of $21.33.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.